People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...

GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...

What Are GLP-1s? Glucagon-like peptide-1 receptor agonists, also known as GLP-1 drugs, are a class of medications that mimic the action of ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a GLP-1 receptor agonist, ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be ...

Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus nephritis may reduce the risk of progression to end-stage kidney disease (ESKD), according to a poster presentation ...

Glucagon-like peptide-1 (GLP-1) receptor agonists can stop people from developing kidney complications, new research has ...

A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...